Mike Mentesana Email & Phone Number

Mike Mentesana is a Founder at Wilbury Ventures based in New York, New York, United States, North America. Michael is a seasoned executive, innovator, and venture investor with over 25 years of experience in the biopharmaceutical industry. He is a recognized leader in corporate restructuring, product development, M&A, R&D transformation, and advanced analytics, driving strategic initiatives across top pharmaceutical companies, CROs, biotech startups, leading provider networks, public health organizations, and the FDA. He has a proven track record of delivering measurable financial impact, including over $50M in cost reductions, $25M+ in EBITDA improvements, and a 15% increase in R&D productivity for global pharmaceutical companies. He led R&D operational transformations for 18 of the top 25 pharma companies, optimizing portfolio management, resource planning, and financial governance. Through Wilbury Ventures, with PE/VC-backed startups, Michael serves as a board member, investor, and strategic partner. Through this work, he partners with VieCure, NPower Medicine, BLC, Key Benefits, Aktana, Catalytic, RxE2 and many others, providing guidance on growth strategy, product innovation, and market expansion. He also serves on the advisory boards of Ocean Genomics and the Rockefeller Neuroscience Institute. Previously, Michael played a pivotal role in Syapse, evolving from Board Member to Senior Advisor, then President, and ultimately CEO. As CEO, he restructured the company, implemented a new strategic vision, and led its successful acquisition by NPower Medicine. Prior to Syapse, he co-founded and served as the founding CEO of Nextec Neuroscience, driving the development of breakthrough therapies for neuro-oncology and neurodegenerative diseases. At PwC, he founded and led the Pharma R&D and Health Analytics practices, transforming them into $100M+ annual revenue businesses. His M&A expertise includes leading major post-merger integrations, divestitures, and deal strategy for landmark transactions like Celgene-BMS, AstraZeneca-MedImmune, and the Otezla divestiture. Earlier in his career, he founded Intendere Consulting and held senior roles at Deloitte Consulting. Michael is known for his ability to deliver measurable financial results, build high-performing teams, and drive operational efficiency. His leadership fosters product innovation, accelerates go-to-market strategies, and enhances deal value. He remains an active contributor to thought leadership and industry forums. Michael holds dual bachelor’s degrees in Organizational Psychology and Biology from Brooklyn College and a master’s in Organizational & Behavioral Psychology from Columbia University.